Top Health Tech Companies in Dublin (87)
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.
Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.
Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.
Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.
Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.
LGC is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. Its high quality product portfolio is comprised of mission-critical tools for genomic analysis and for quality assurance applications, which are typically embedded and recurring within our customers’ products and workflows and are valued for...
LGC's Top Stability & Growth Strengths
Strong Market Position & Advantage: Holding the UK’s National Measurement Laboratory designation and Government Chemist role, plus leading positions in reference materials, proficiency testing, and agrigenomics/genotyping, reinforces defensible niche leadership. Acquisitions and widespread adoption of technologies like KASP genotyping underscore recognized authority in core segments.
Strong Revenue Growth: Reported revenue increased year over year in FY25, reversing the prior year’s dip. Adjusted EBITDA also rose, indicating improved top-line momentum alongside better operating results.
Future-Ready Strategy: Large-scale site expansions (Toronto, Guildford, Berlin) and integration of recent acquisitions point to capacity build-out and a scale-focused operating model. A new CEO, business-unit consolidation, and an Innovation Hub signal intent to sustain growth through portfolio development and execution.
MEG is a healthcare digital quality management system, used by healthcare providers in 15+ countries to simplify and streamline time-consuming care quality, patient safety, and accreditation processes across their organisations. Tools for audit, incident, risk, action planning, complaints, feedback surveys and documents and reporting are all conveniently managed on any device from one central location. Save time, gain real-time reporting...
Using the latest technology Allview Healthcare gives you access to leading Consultant Dermatologist and surgical services Rapid diagnosis and results within weeks Specialising in Skin Cancers, Moles, Rash, Acne and Lesions
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
When a patient is critically ill, giving their doctor the right information at the right time can mean the difference between life and death. At Novus Diagnostics, we are developing ground-breaking diagnostics technologies to provide rapid answers right at the patient’s bedside. Our first product, SepTec, will help tackle the global challenge of sepsis which kills more than 11 million...
Optum Insight provides technology-enabled services, advanced analytics, and platforms focused on the healthcare system to help customers reduce costs, manage risk and quality, and grow revenue. It aims to simplify and connect clinical, administrative, and financial processes within healthcare.
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of...
Bristol Myers Squibb's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests BMS holds a top‑tier global position with anchor franchises like Eliquis and Opdivo and a broad oncology footprint including cell therapies, reinforcing sustained competitive advantage.
Product Line Growth: Feedback suggests the company’s “growth portfolio” of newer medicines is expanding strongly, with assets such as Reblozyl, Breyanzi, Camzyos, Opdualag and Cobenfy helping to offset legacy declines.
Future-Ready Strategy: Feedback suggests recent acquisitions and collaborations (Karuna/Cobenfy, RayzeBio, Mirati, BioNTech) broaden modalities and late‑decade growth drivers, positioning the company to sustain leadership beyond current headwinds.
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and...
Sanofi's Top Stability & Growth Strengths
Strong Revenue Growth: Sales growth is described as strong, with 2025 net sales up at constant exchange rates and Q4 showing further acceleration, indicating momentum into 2026.
Profitability: Earnings expansion is described as outpacing sales growth in 2025, and 2026 guidance indicates continued profitable expansion with EPS growing slightly faster than sales.
Product Line Growth: Newer launches are scaling rapidly, with notable growth in recent pharma launches and contributions from products beyond the flagship franchise, helping broaden growth drivers.
Affidea is a pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider, operating in Greece since 2005 to offer high-quality, integrated primary health services.
At Vertigenius™️, we're pioneering the integration of technology and healthcare to address vestibular disorders, improving balance and reducing dizziness. Our innovative approach includes a clinician portal, a patient app, and a wearable head sensor, making rehabilitation accessible and efficient.
We enable Cardiologists to save lives through exceptional decision-making accuracy
Swiftqueue Enterprise Scheduling is like Air Traffic Control for Healthcare Appointments and Referrals. Our Patient First solutions deliver co-ordinated healthcare appointments and referral management in Ireland, UK & USA. We have helped our customer's significantly reduce the cost of clinic administration and deliver a demonstrable ROI. Our rapid deployment templates and integration APIs can deliver results for our customers in...
Spectrum.Life is a mental health and wellbeing innovator on a mission to change and protect as many lives as possible; delivering digital solutions for Corporate, Insurance and University Sectors. Spectrum.Life supports 2.5m users across 2,500 clients across Ireland & the UK. Our solutions are clinically backed and ensure that there is something for everyone- for wherever they are on the...
Eirdoc Online Doctor: Your Convenient Gateway to Quality Healthcare. Experience the ease and accessibility of online healthcare with Eirdoc Online Doctor. Our team of experienced and qualified physicians is available to provide immediate GP consultations via video or telephone, ensuring that your health remains a top priority without disrupting your busy schedule.
Sia Partners is a next generation management consulting firm and pioneer of Consulting 4.0. We offer a unique blend of AI and design capabilities, augmenting traditional consulting to deliver superior value to our clients. Counting 1,800 consultants in 18 countries, we expect to achieve USD 300 million in turnover for the current fiscal year. With a global footprint and expertise...
Sia Partners's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent investment by Blackstone of up to €250 million in December 2024 provides growth capital and signals external confidence in the firm’s expansion plans. Company statements link this funding to accelerating U.S. growth, M&A, and AI-enabled offerings.
Market Expansion: Multiple acquisitions and a sustained U.S. push (e.g., Notion Consulting, Ready Set Rocket, Precedence, Kaiser Associates) indicate ongoing geographic and service-line expansion across North America and Europe. Leadership attention to the U.S. market and a growing office footprint suggest increased depth in key geographies.
Innovation-Driven Growth: The firm is productizing AI (e.g., SiaGPT and 800+ deployable AI agents by April 2026) and launching new lines like Corporate Strategy, PE & M&A, pointing to growth via differentiated, tech-enabled delivery. Partnerships and ecosystem recognition around NVIDIA and AWS reinforce momentum in AI-driven consulting.
Ipsen is a French leading global mid-size biopharmaceutical company headquartered in Paris, France focusing its efforts where unmet medical needs are greatest. Ipsen develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Rare Disease and Neuroscience. We have over 5000 employees worldwide and our medicines are registered in more than 100 countries, with direct commercial presence in...
Ipsen's Top Stability & Growth Strengths
Strong Revenue Growth: Reported results show double-digit growth at constant exchange rates in 2024 and 2025 with an accelerated start in Q1 2026, and guidance indicates continued expansion in 2026. This momentum spans all three therapeutic areas rather than a single product.
Profitability: Disclosures highlight expanding core operating margins above the mid-30s and rising core operating income. Guidance continues to target strong margins alongside growth.
Diversified Revenue Streams: Recent updates indicate contributions from Oncology, Rare Disease, and Neuroscience, with products excluding Somatuline growing strongly and rare disease accelerating. Strategic acquisitions and partnerships have broadened the base beyond any single legacy brand.
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion...
